Figure legends lists
Figure 1. Flowchart of patient selection
Figure 2. The progression-free survival (PFS) curves of
patients with baseline HBV DNA level ≤2000IU/mL and those with DNA level
> 2000IU/mL receiving anti-PD-1 in combination with
antiangiogenic therapy
Figure 3. Univariate and multivariate cox analyses of
progression-free survival (PFS) stratified by baseline characteristics
Figure 4. Among the 70 patients, 2 had HBV reactivation. A.
Characteristics of the 2 patients with HBV reactivation; B. Kinetics of
HBV DNA in the 2 patients with HBV reactivation